engage checkpoint medical linkedin twitter

The Role of PARP Inhibition in Prostate Cancer: e-Learning Now Available

The Role of PARP Inhibition in Prostate Cancer: e-Learning Now Available

Prof. Emmanuel S. Antonarakis, Dr. Neal D. Shore, Prof. Andrew J. Armstrong

The range of therapeutic options in prostate cancer is expanding, including strategies for PARP inhibition.
Portrait of Emmanuel S. Antonarakis
Prof. Emmanuel S. Antonarakis

Medical Oncologist

Johns Hopkins Medicine

United States (US)

Portrait of Neal D. Shore
Dr. Neal D. Shore


Carolina Urologic Research Centre and GenesisCare

United States (US)

Portrait of Andrew J. Armstrong
Prof. Andrew J. Armstrong

Medical Oncologist

Duke University School of Medicine

United States (US)

preview next

time E-learning | open 60 min |accreditation: EACCME

download resources

I agree that this educational programme:

Was valuable to me:


The aim of this e-learning course is to provide an understanding of the mechanism of action of PARP inhibitors; the prevalence of DNA damage repair (DDR) mutations in advanced prostate cancer, as well as approaches for somatic and germline testing to identify patients with these mutations; and the recent and ongoing clinical trial data on PARP inhibition in advanced prostate cancer. Watch this video from Dr. Neal D. Shore and download the educational slides to learn more. Follow the link above to start your e-learning journey today.


This course has been developed by the following expert faculty:

  • Dr. Neal D. Shore, Carolina Urologic Research Center (Myrtle Beach, South Carolina, USA)

  • Prof. Andrew J. Armstrong, Duke University School of Medicine (Durham, North Carolina, USA)

  • Prof. Emmanuel S. Antonarakis, Johns Hopkins Medicine (Baltimore, Maryland, USA)

Other programmes of interest